Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - American Depositary Shares (NQ:ASND)

202.00 +0.99 (+0.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
 
Via Benzinga
Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock?
A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND). 
Via Chartmill
If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
Why Is BioMarin Stock Trading Higher On Thursday?
BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results. 
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
 
Via Benzinga
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target. 
Via Benzinga
Earnings Scheduled For February 12, 2025
 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
 
Via Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing
The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp. 
Via Stocktwits
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
(ASND) - Analyzing Ascendis Pharma's Short Interest
 
Via Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
 
Via Benzinga
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date. 
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
 
Via Benzinga
Looking Into Ascendis Pharma's Recent Short Interest
 
Via Benzinga
Earnings Scheduled For November 14, 2024
 
Via Benzinga
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments. 
Via Benzinga
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
3 Oversold Stocks with Big RSI Rebound Potential
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them. 
Via MarketBeat
Topics Economy
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
Via Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
 
Via Benzinga
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. 
Via Benzinga
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
 
Via Benzinga
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback